JPRN-jRCT2080220294未知3 期
To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 Diabetes
ovartis Pharma K.K.0 个研究点目标入组 370 人开始时间: 2006年9月4日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 370
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Ages Eligible for Study: 20 Years and above, Genders Eligible for Study: Both
- •Inclusion Criteria:
- •- Diagnosis of type 2 diabetes
- •- Patients who have been placed on diet and exercise therapy without achieving target blood glucose levels
- •- Outpatients
排除标准
- •- Type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes
- •- Significant heart diseases
- •- Significant diabetic complications
- •Other protocol-defined inclusion/exclusion criteria may apply
研究者
相似试验
招募中
不适用
Comparison of efficacy and safety of Vildagliptin and Teneligliptin in patients with Type 2 Diabetes MellitusCTRI/2017/02/007766jawaharlal nehru medical college and hospital160
已完成
4 期
Comparison of utility of Viladagliptin 50 mg tablet twice daily and metformin combination therapy with Vildagliptin 100 mg sustained release tablet once daily and metformin combination therapy in Indian patients with type 2 diabetes mellitus: A randomized open label phase IV clinical trialCTRI/2021/10/037574Dr Rudra Paul
未知
1 期
To Assess the Efficacy and Safety of Vildagliptin in Patients with Type 2 DiabetesType 2 DiabetesJPRN-jRCT2080220150ovartis Pharma K.K.264
招募中
4 期
An study to assess the safety and efficacy of vildagliptin vs voglibose in management of post-prandial blood sugar in patients with T2DMCTRI/2024/08/072355Dr Mahima V
未知
3 期
To assess the efficacy and safety of vildagliptin as add-on therapy to sulfonylurea in patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapyType 2 DiabetesJPRN-jRCT2080220244ovartis Pharma K.K.200